康弘药业 (002773)
Chengdu Kanghong Pharmaceutical Group Co., Ltd
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 92130.00
- Circulating A-Shares(W): 68681.30
- Earnings Per Share(RMB): 1.1200
- Net Assets Per Share(RMB): 9.9494
- Operating Revenue(W RMB): 362386.57
- Total Profit(W RMB): 120845.07
- Net Profit Attributable to Parent(W RMB): 103290.66
- Net Profit Growth Rate(%): 6.08
- Weighted Return on Equity(%): 11.5500
- Operating Cash Flow Per Share(RMB): 1.5290
- Undistributed Profit Per Share(RMB): 6.1902
- Capital Reserve Per Share(RMB): 2.2016
2. Main Business
The main business covers:
- R&D, production and sales of biological products
- R&D, production and sales of traditional Chinese medicines
- R&D, production and sales of chemical drugs
- R&D, production and sales of ophthalmic medical devices
3. Company Basic Information
- Company Name: Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Listing Date: 2015-06-26
- Industry: Pharmaceutical Manufacturing
- Address: No. 108 Shuxi Road, Jinniu District, Chengdu City, Sichuan Province
- Website: www.cnkh.com
- Company Profile: The predecessor of Chengdu Kanghong Pharmaceutical Group Co., Ltd. was Chengdu Yierkang Pharmaceutical Co., Ltd., which was established through the restructuring of the state-owned enterprise Chengdu Jimin Pharmaceutical Factory. In December 1998, Chengdu Yierkang Pharmaceutical Co., Ltd. was renamed Chengdu Daxinan Pharmaceutical Co., Ltd. On January 19, 2001, the People's Government of Sichuan Province approved the overall change of Chengdu Daxinan Pharmaceutical Co., Ltd. into Chengdu Daxinan Pharmaceutical Co., Ltd. (joint stock company). On March 6, 2008, with the approval of the Chengdu Administration for Industry and Commerce, Daxinan Co., Ltd. was renamed "Chengdu Kanghong Pharmaceutical Group Co., Ltd."
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Chengdu Kanghong Technology Industry (Group) Co., Ltd. | General Legal Person | 29201.49 | 42.52 |
| 2 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 2800.70 | 4.08 |
| 3 | Dacheng Ruixiang Hybrid Securities Investment Fund Class A | Fund | 1102.33 | 1.60 |
| 4 | Dacheng Competitive Advantage Hybrid Securities Investment Fund Class A | Fund | 1034.56 | 1.51 |
| 5 | Dacheng Strategy Return Hybrid Securities Investment Fund Class A | Fund | 909.82 | 1.32 |
| 6 | Orient Securities Medical Upgrade Equity Initiated Securities Investment Fund Class A | Fund | 629.59 | 0.92 |
| 7 | Great Wall Medical Industry Select Hybrid Initiated Securities Investment Fund Class A | Fund | 251.60 | 0.37 |
| 8 | Xingquan CSI 300 Index Enhanced Securities Investment Fund (LOF) Class A | Fund | 188.18 | 0.27 |
| 9 | Baoying Medical and Health Shanghai-Hong Kong-Shenzhen Equity Securities Investment Fund Class A | Fund | 179.05 | 0.26 |
| 10 | Qianhai Kaiyuan Traditional Chinese Medicine Research Select Equity Initiated Securities Investment Fund Class A | Fund | 149.72 | 0.22 |
5. Concept Sectors
- Generic Drugs
- Innovative Drugs
- Synthetic Biology
- Margin Trading & Securities Lending
- Blue-Chip Stocks
- Heavy Holdings by Northbound Capital
- SME 100
- Small-Cap Growth
- Small-Cap Value
- SZSE 300
- SZSE Growth
- SZSE Value
- SZSE Growth Index
- SME 300
- SZSE Innovation
- Innovation 100
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information